Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Ethical Drug Market in Japan Grew 1.6% to ¥9,035,806 Mil. in FY2010: IMS Japan
July 4, 2011
- METI Advisory Committee Proposes Exclusion of OTC-like Drugs from Insurance Coverage
July 4, 2011
- Sprycel Approved as 1st-line Treatment for CML: Bristol-Myers, Otsuka
July 4, 2011
- Wakamoto Licenses Ophthalmic Surgical Adjuvant from Kyushu Univ. Bioventure
July 4, 2011
- PMDA to Give Priority to Regenerative Medicine, Cancer in Regulatory Strategy Consultation
July 4, 2011
- Number of Deaths Reached Post-war High in 2010: Korosho
July 4, 2011
- Astellas Transfers Luvox to Abbott Japan
July 4, 2011
- Korosho Asks Takeda to Revise Package Insert for Actos
July 4, 2011
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- Nycomed Takes Over Bisphosphonate from Roche
June 27, 2011
- Takeda to Start PIII Trial for Hib Vaccine
June 27, 2011
- Eiken: Sales Up 2.7% Driven by Extraordinary Demand due to Disaster
June 27, 2011
- NanoCarrier to Obtain Substance Patent for pH-Responsive Micelles
June 27, 2011
- Otsuka to Start PI for Cancer Vaccine OCV-105 in Japan
June 27, 2011
- Takara Bio: Sales Down 3.0% due to Decline in Sales of Scientific Instruments
June 27, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…